Medical Imaging in Clinical Trials (eBook)
XVIII, 420 Seiten
Springer London (Verlag)
978-1-84882-710-3 (ISBN)
In the last few years the use of medical imaging has increased exponentially in routine clinical practice. This has been reflected in a rapidly increasing use of medical imaging in clinical trials, through all phases. More recently this has culminated in a number of inter-disciplinary meetings with the various stake holders, including the FDA. Changes in the regulatory process has resulted, when it comes to the submission of data to the FDA, in a therapeutic agent where one or more of the trial end-points is the assessment of a radiological end-point. No longer is it sufficient to have the images read by the local investigator site.
The FDA has also identified Medical Imaging as one of the key 6 points in the Critical Path initiative which was launched in 2004. This puts a keen focus on the role of imaging and the need to clearly identify and understand this aspect of clinical trials.
As the pharmaceutical, biotech and medical device industry continues to identify ways to improve and speed up product development, medical imaging plays a more significant role. An understanding of the methodology and the metrics is therefore required but difficult to ascertain in one easy to read volume for individuals entering this field. This book will therefore fulfill this void, be it for the pharmaceutical personnel from medical director to monitor, or the Principal Investigator who is having to understand the complexities of the imaging and why it is having to be sent off-site for a 'central read.'
In the last few years the use of medical imaging has increased exponentially in routine clinical practice. This has been reflected in a rapidly increasing use of medical imaging in clinical trials, through all phases. More recently this has culminated in a number of inter-disciplinary meetings with the various stake holders, including the FDA. Changes in the regulatory process has resulted, when it comes to the submission of data to the FDA, in a therapeutic agent where one or more of the trial end-points is the assessment of a radiological end-point. No longer is it sufficient to have the images read by the local investigator site.The FDA has also identified Medical Imaging as one of the key 6 points in the Critical Path initiative which was launched in 2004. This puts a keen focus on the role of imaging and the need to clearly identify and understand this aspect of clinical trials.As the pharmaceutical, biotech and medical device industry continues to identify ways to improve and speed up product development, medical imaging plays a more significant role. An understanding of the methodology and the metrics is therefore required but difficult to ascertain in one easy to read volume for individuals entering this field. This book will therefore fulfill this void, be it for the pharmaceutical personnel from medical director to monitor, or the Principal Investigator who is having to understand the complexities of the imaging and why it is having to be sent off-site for a 'central read.'
Part I: Overview and Trial Management.- 1. Medical Imaging Modalities.- 2. The Metrics and New Imaging Marker Qualification in Medical Imaging Modalities.- 3. Radiation Risks and Dosimetry Assessment.- 4. Imaging Review Charters and Operational Considerations.- 5. Defining the Radiological Blinded Read and Adjudication.- 6. Medical Imaging in Drug Development.- 7. Evaluating and Working with an Imaging Core Laboratory.- Part II: Therapeutic Specifics of Medical Imaging.- 8. Monitoring Responses to Therapy in Oncology.- 9. Cardiac Imaging in Clinical Trials.- 10. Neuroimaging in Clinical Trials.- 11. Imaging in Musculoskeletal, Metabolic, Endocrinological, and Pediatric Clinical Trials.- 12. Body Composition.- 13. Optical Coherence Tomography as a Biomarker in Clinical Trials for Ophthalmology and Neurology.- 14. Nuclear Medicine: An Overview of Imaging Techniques, Clinical Applications, and Trials.- 15. Contrast Agents in Radiology.- Part III: The Future of Imaging in Clinical Trials.- 16. Pharmaceutical Industry Perspective Regarding Imaging Techniques.
Erscheint lt. Verlag | 30.1.2014 |
---|---|
Zusatzinfo | XVIII, 420 p. 111 illus., 57 illus. in color. |
Verlagsort | London |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
Medizinische Fachgebiete ► Radiologie / Bildgebende Verfahren ► Radiologie | |
Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
Studium ► 2. Studienabschnitt (Klinik) ► Anamnese / Körperliche Untersuchung | |
Schlagworte | diagnostic radiology • ultrasonography |
ISBN-10 | 1-84882-710-5 / 1848827105 |
ISBN-13 | 978-1-84882-710-3 / 9781848827103 |
Haben Sie eine Frage zum Produkt? |
Größe: 21,8 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich